NCT05851677招募中不适用
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Progression-Free Survival
研究概览
简要总结
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed breast cancer;
- •Prior or current use of Disitamab vedotin (RC48-ADC);
排除标准
- •Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
研究组 & 干预措施
RC48-ADC
RC48-ADC for breast cancer
干预措施: Disitamab vedotin (Drug)
结局指标
主要结局
Progression-Free Survival
时间窗: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
次要结局
- Adverse events(From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year))
研究者
Wenjin Yin
Deputy Chief of Breast Surgery Department
RenJi Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
RC48-ADC in HER2-low Advanced Breast CancerAdvanced Breast CancerNCT05831878RenJi Hospital36
尚未招募
不适用
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain MetastasisBreast CancerNCT06015113Xi'an International Medical Center Hospital20
招募中
3 期
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)HR Positive/HER2 Low Expression Metastatic Breast CancerNCT05904964Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University288
招募中
2 期
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyGastroesophageal Junction AdenocarcinomaGastric CancerNCT06221748RemeGen Co., Ltd.90
招募中
2 期
RC48 in Combination With AK104 and Bevacizumab in OCCCOvary CancerNCT06540729Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University39